Clinical and biochemical presentations of polycystic ovary syndrome among obese and nonobese women.
OBJECTIVE
To study the differences in clinical and biochemical characteristics between obese and nonobese women with polycystic ovary syndrome (PCOS).


METHODS
Retrospective study.


METHODS
University teaching hospital.


METHODS
Four hundred sixty-four Taiwan Chinese women, among whom 295 were diagnosed with PCOS and 169 were non-PCOS controls.


METHODS
Body mass index, average menstrual interval, modified Ferriman-Gallwey score, acne, total T, and waist-to-hip ratio.


RESULTS
Obese women with polycystic ovary morphology (PCOM) had a greater risk of developing of PCOS (odds ratio [OR], 2.5; 95% confidence interval [CI], 1.5-10.4) than nonobese women with PCOM. Obese women with PCOM had a higher incidence oligomenorrhea (OR, 2.6; 95% CI, 1.6-4.1) and biochemical hyperandrogenemia (OR, 2.5; 95% CI, 1.6-4.0) than nonobese women with PCOM. Obese subjects with PCOS had a higher risk of developing oligomenorrhea (OR, 2.2; 95% CI, 1.3-3.7) and biochemical hyperandrogenemia (OR, 2.6; 95% CI, 1.6-4.2) than nonobese women with PCOS. Moreover, obese women with PCOS had significantly higher serum total T levels and more prolonged menstrual intervals than nonobese women with PCOS. Notably, the obese women with PCOS presented less acne than the nonobese subjects (OR, 0.5; 95% CI, 0.3-0.9).


CONCLUSIONS
Obese women with PCOS had more severe ovulatory dysfunction and higher serum total T levels than nonobese subjects. Moreover, obese women with PCOS had a significantly lower frequency of acne than nonobese subjects.
Liou
Tsan-Hon
TH
Obesity Research Center, Taipei Medical University-Wan Fang Medical Center, Taipei, Taiwan.
Yang
Jen-Hung
JH
Hsieh
Ching-Hung
CH
Lee
Ching-Yin
CY
Hsu
Chun-Sen
CS
Hsu
Ming-I
MI
D000152:Acne Vulgaris / Q000453:epidemiology; D000293:Adolescent; D000328:Adult; D015992:Body Mass Index; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006628:Hirsutism / Q000453:epidemiology; D006801:Humans; D017588:Hyperandrogenism / Q000453:epidemiology; D015994:Incidence; D007986:Luteinizing Hormone / Q000097:blood; D008598:Menstruation; D009765:Obesity / Q000453:epidemiology*; D009839:Oligomenorrhea / Q000453:epidemiology; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000453:epidemiology* / Q000503:physiopathology*; D011388:Prolactin / Q000097:blood; D012307:Risk Factors; D013624:Taiwan / Q000453:epidemiology; D013739:Testosterone / Q000097:blood; D055815:Young Adult
D013739:Testosterone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone